Volume 3 Issue 2 - 2019
Osteoporosis Treatments
Da-Yong Lu and Jin-Yu Che*
Shanghai University, Shanghai 200444, PRC
*Corresponding Author: Da-Yong Lu, Shanghai University, Shanghai 200444, PRC.
Receieved: March 11, 2019; Published: March 21, 2019
The prevalence of osteoporosis in old people is a serious healthcare problem globally. This editorial introduces general medical intervention against human osteoporosis.
Keywords: Osteoporosis; Drug development; Clinical diagnosis; Biology medication
Osteoporosis-induced bone-fracture and immovability has high possibility of human mortality [1-3]. Variability of osteoporosis prevention and treatments between old people and young adults asks for different therapeutics in the clinic [4]. We wish that doctors and patients may do more for therapeutic variability.
Table 1 represents these differences [5-12];
Patients ages Physio-pathological characters Major nutrition or therapies
Teenage Nutritional-insufficient individuals Mineral or food supports
Young adults Bone pain and vulnerable to attack Sports/less sedentary
Middle-ages Bone pain and osteoporosis Chemical drug or vitamin
Old people Serious osteoporosis/immobility Bio-therapy + hormone + new therapeutics
Table 1: The different symptoms and therapeutics among varied patient ages.
Future Direction
Osteoporosis treatments for old people is very difficult because they are refractory to almost all conventional medications. New ideas must be created to counteract these therapeutic limitations.
Targets to co-morbidity [10].
Precision and personalized medicine innovation [13-14]
Better nursery work [15]
New drug development [16-19]
Math-therapeutic modality establishments for train medical students/junior doctors and clinical therapeutic promotion [11]
And others
In summary, therapeutic selection and novel drug developments are key issues for continuing improvements of osteoporosis treatments.
  1. Lu DY., et al. “Bone disease recovery strategies, An overview”. EC Orthopaedics 10.1 (2019): 1-3
  2. Melton J. “Hip fracture; a worldwide problem today and tomorrow” Bone 14(1993); S1-8
  3. Silva DMW. “Diagnosis of osteoporosis; bone mineral density, risk factors, or both”. EC Orthopaedics 9. 7 (2018): 500-502
  4. Lu DY., et al. “Osteoporosis in old women, therapeutic selection”. EC Orthopaedics 9. 7 (2018): 386
  5. Kikuchi H., et al. “A real-world pilot study on Zoledronate-based treatment of osteoporosis in lapanese women aged over 65 years including very advanced age”. EC Orthopaedics. 10. 3 (2019): 153-156
  6. Choudhary D and Alam A. “Anti-osteoporotic activity of bioactive compounds from Iris germanica targeting NF-Kappa B”. EC Pharmacology & Toxicology 6. 8 (2018): 665-678
  7. Lu DY., et al. “Osteoporosis, importance for early diagnosis and treatments”. EC Orthopaedics 9. 9 (2018): 624-625
  8. Khan N and Khatosh S. “Use of vitamin D supplements in Middle East countries: The need of the hour”. EC Nutrition 13. 9 (2018): 596-599
  9. Moghaddam MBP. “A definitive prevention and treatment of osteoporosis through genetic therapy”. EC Orthopaedics 10. 3 (2019): 159-161
  10. Lu DY., et al. “Clinical treatments of osteoporosis, how to target co-morbidities”. EC Orthopaedics. 9 .11 (2018): 781-782
  11. Lu DY., et al. “Bone disease treatments, math-therapeutic modality”. EC Orthopaedics 10 .3 (2019): 140-143.
  12. Putta S., et al. “Anthocyanins: Possible role as multitarget therapeutic agents for prevention and therapy of chronic diseases”. Current Pharmaceutical Design 23 .30 (2017): 4475-4483
  13. Lu DY, Lu TR, Che JY, Yarla NS. “Individualized cancer therapy, what is the next generation?” EC Cancer 208, 2 (6), 286-297
  14. Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics & Personalized Medicine 16 .2 (2018): 156-163
  15. Lu DY., et al. “Patients care and nursery in different diseases”. Hospice and Palliative Medicine International Journal  3 .1 (2019): 28-30
  16. Penalvo JL., et al. “The potential impact of food taxes and subsidies on cardiovascular disease and diabetes burden and disparities in the United States”. BMC Medicine 15. 1 (2017): 208
  17. Rokita E., et al. “Bone mineralization after strontium and fluoride treatment in osteoporosis”. Nuclear Instruments and Methods in Physics Research. Section B Beam Interactions with Materials and Atoms 158 (1-4) (1999): 412-417
  18. Kuang GM., et al. “Augmentation of a locking plate system using bioactive bone cement—experiment in a proximal humeral fracture mode”. Geriatric Orthopaedic Surgery Rehabilitation 9 .1 (2018): 1-8
  19. Sethmann I., et al. "Development of phosphaticed calcium carbonate biominerals as bioactive bone graft substitute materials, Part I: Incorporation of magnesium and strontium ions”. Journal of  Functional Biomaterials. 9.4, 69 DOI (2018): 10.3390/jfb904069
Citation: Da-Yong Lu and Jin-Yu Che. “Osteoporosis Treatments”. Clinical Biotechnology and Microbiology 3.2 (2019): 612-614.
Copyright: © 2019 Da-Yong Lu and Jin-Yu Che. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.